ALTAMIRA THERAPEUTICS
Altamira Therapeutics is dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus, and restore balance. Altamira Therapeutics is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.
ALTAMIRA THERAPEUTICS
Social Links:
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2003-04-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.altamiratherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+41 61 201 13 50
Email Addresses:
[email protected]
Total Funding:
122.54 M USD
Technology used in webpage:
Euro SPF Amazon IPv6 Microsoft Exchange Online Cloudflare JS Office 365 Mail CDN JS AJAX Libraries API Microsoft Azure DNS
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Arsenal Medical
Arsenal Medical develops novel products that improve local therapy for injuries and diseases.
Cheplapharm Arzneimittel
Cheplapharm is a pharmaceutical company that offers branded drugs, medical products, supplements, and cosmetics.
Closed Loop Medicine
Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians
electroCore
ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.
Enterprise Therapeutics
A UK-based developer of drugs to treat respiratory diseases
InflaRx
InflaRx develops new therapeutics in the field of acute and chronic inflammation.
Mithra Pharmaceuticals SA
Mithra Pharmaceuticals SA specializes in the development of women's health care products.
ReCor Medical
ReCor Medical has developed a unique therapeutic non-focused ultrasound system
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-03 | Trasir Therapeutics | Trasir Therapeutics acquired by Altamira Therapeutics | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Altamira Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Series C - Altamira Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series C - Altamira Therapeutics
ZKB Pharma Vision Fund
ZKB Pharma Vision Fund investment in Series B - Altamira Therapeutics
Idinvest Partners
Idinvest Partners investment in Series B - Altamira Therapeutics
Lacuna
Lacuna investment in Series B - Altamira Therapeutics
Idinvest Partners
Idinvest Partners investment in Series A - Altamira Therapeutics
Official Site Inspections
http://www.altamiratherapeutics.com Semrush global rank: 5.27 M Semrush visits lastest month: 1.46 K
- Host name: lx20.hoststar.hosting
- IP address: 168.119.41.54
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Altamira Therapeutics"
Altamira Therapeutics Provides Investor and Business Update
HAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business …See details»
Altamira Therapeutics - LinkedIn
Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhoreâ„¢ / SemaPhoreâ„¢ delivery platforms).See details»
Investors & Media - Altamira Therapeutics
Apr 12, 2022 Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern. Company pivots towards RNA therapeutics and its OligoPhoreâ„¢ / SemaPhoreâ„¢ …See details»
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results …
May 12, 2023 Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. To …See details»
Altamira Therapeutics - RNA Therapeutics
In the US in 2014, approximately 1.3 million adults suffered from RA (Hunter et al., 2017) and according to the World Health Organization (WHO), the autoimmune disease affects globally …See details»
Altamira Therapeutics to Develop Novel Generation of …
Jul 25, 2022 [email protected]. 800-460-0183 . 1 Hunter TM et al. (2017), Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims …See details»
Altamira Therapeutics Provides Business Update and First Half …
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration …See details»
Altamira Therapeutics Provides Business Update - GlobeNewswire
Aug 30, 2022 [email protected] 800-460-0183. 1 National Ambulatory Medical Care Survey 2 www.ibisworld.com 3 Centers for Disease Control and Prevention 4 …See details»
Altamira Therapeutics’ CEO Interviewed by Proactive Investors to ...
HAMILTON, BERMUDA -- August 3, 2022 -- Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important …See details»
Newsroom - Altamira Therapeutics
Targeting Cancer with RNA Therapeutics DDN, September 2021, Volume 17, Issue 9See details»
Altamira Therapeutics to Host Investor Call on September
Sep 8, 2022 Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. Access: Toll-free dial-in number: 1-877-545 …See details»
Altamira in strategic repositioning to develop RNA therapeutics
Aug 3, 2021 Altamira in strategic repositioning to develop RNA therapeutics August 3, 2021 · Leonard Zehr Altamira Therapeutics (NASDAQ:CYTO) is using its recent acquisition of closely-See details»
Altamira Therapeutics Announces Extended ISO 13485 Quality …
Sep 27, 2024 ISO 13485 is an internationally recognized standard for quality management systems in the medical device industry. It specifies requirements for a quality management …See details»
Altamira Therapeutic's SemaPhore Platform Shown - GlobeNewswire
Jul 19, 2022 Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatments; Demonstrates effective uptake and transfection capacity of …See details»
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® …
Nov 17, 2023 Altamira has agreed to sell the 51% stake in Medica for a cash consideration of CHF 2,040,000 (about $2.3 million) and will retain 49% of the company’s share capital.See details»
Investors & Media - Altamira Therapeutics
Apr 10, 2023 Published meta-analysis shows statistically significant improvement in dizziness handicap for betahistine treatment over standard of care procedure alone in patients suffering …See details»
Investors & Media - Altamira Therapeutics
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhoreâ„¢ delivery technology results in significant …See details»
Altamira Therapeutics to Host First Half 2023 Financial Results and ...
Sep 6, 2023 Event: Altamira Therapeutics First Half 2023 Financial Results and Business Update Call Date: Tuesday, September 12th Time: 8am ET (5am PT). Access:. Toll Free: 888 …See details»
Investors & Media - Altamira Therapeutics
Feb 14, 2022 75 patients randomized in Part B of study to receive either intranasal betahistine or placebo Top-line results from the trial expected to be announced in Q2-2022 HAMILTON, …See details»